Faricimab + PRP vs. Vitrectomy + Endolaser for PDR Treatment

Recruiting Phase 3 NCT06790784

Study Description

A Study Comparing Two Treatment Approaches for Proliferative Diabetic Retinopathy

Study Details

Registry ID:
NCT06790784
Conditions:
Proliferative Diabetic Retinopathy (PDR)
Phase:
Phase 3
Target Enrollment:
426 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (34 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →